TMCnet News
Beyond Cellular Models: Longevica Capitalizes on World's Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan PipelineLongevica Therapeutics, a biotechnology company bridging the translation gap between empirical geroscience and human therapeutics, today announced the formation of its Scientific Advisory Board (SAB). Featuring globally recognized leaders spanning cell signaling, computational phenomics, multi-omics, quantitative pharmacology, medicinal chemistry, clinical trial execution, and biopharma venture capital, the multidisciplinary assembly marks Longevica's operational pivot from foundational discovery and data generation to clinical execution, drug development, and strategic alliance building. While traditional biotech approaches have historically relied on simplified cell lines, short-lived lower organisms, or retrospective data mining, Longevica invested four years and $13 million to execute the world's largest in vivo mammalian screening program at The Jackson Laboratory. By systematically tracking 1,033 small-molecule compounds across more than 16,000 subjects over their natural lifespans, Longevica established an empirical full-lifespan dataset unmatched in scale. Computational and bioinformatic analysis of this dataset has yielded two primary commercial and therapeutic strategies: (1) developing two novel classes of therapeutics based on newly uncovered candidate mechanisms of lifespan extension (LE) to advance health and lifespan, and (2) systematically developing lifespan-extending compounds identified in the screen for several age-related disease indications. The unveiling of the SAB follows the recent appointment of former Genentech, Roche, and NCI/NIH leader Dr. Prasun Mishra as Chief Executive Officer, signaling a concerted biopharmaceutical drive to convert massive phenotypic longevity data into targeted human therapeutics, AI-enabled discovery models, and companion animal applications.
A Multi-Disciplinary Advisory Coalition Built for Translation Longevica's newly appointed Scientific Advisory Board and expert advisors bring specialized, end-to-end expertise spanning fundamental cell biology, computational phenomics, translational medicine, and commercial strategy: Scientific
Clinical
Strategy
Business
Advisory Board Perspective
Dual Therapeutic Strategy & Longevity AI Discovery Engine Armed with 60+ compounds that extended mammalian lifespan by over 10% to 22%, Longevica is advancing a synchronized commercialization matrix: 1. Novel Health-and-Lifespan Therapeutics: Developing two completely new classes of drugs based on two newly discovered mechanisms of lifespan extension (LE) aimed at extending human health-and-lifespan. 2. Targeted Drug Repurposing: Systematically evaluating and developing lifespan-extending molecules from the Jackson Laboratory screening program for traditional age-related therapeutic indications, including cardiovascular, metabolic, fibrotic, and systemic disease. 3. Longevity AI Discovery Engine: Training predictive machine learning algorithms directly on prospective, full-lifespan mammalian outcomes to rapidly reverse-engineer druggable molecular targets and optimize lead candidates without trial-and-error testing. 4. Pet Health-and-Lifespan Interventions: Translating safe, lifespan-extending formulations to preserve mobility, vitality, and health-and-lifespan in companion animals (dogs and cats), delivering accelerated real-world validation and commercial execution. About Longevica Therapeutics Longevica Therapeutics is a preclinical biotechnology company developing small-molecule therapeutics for human and companion-animal health at the intersection of translational aging science, empirical mammalian phenomics, and AI-drug discovery. The company's discovery platform is built on a $13 million, four-year full-lifespan in vivo mammalian longevity screening program conducted at The Jackson Laboratory, evaluating 1,033 small-molecule compounds across more than 16,000 mouse subjects over their natural lifespans. By integrating this proprietary dataset with multi-omics analysis, artificial intelligence, and computational chemistry, Longevica is working to identify and validate aging-associated mechanisms, druggable targets, and therapeutic opportunities. Supported by an advisory board comprising leaders from Harvard University, UC Berkeley, Rutgers University, and the life sciences venture capital sector, Longevica is advancing foundational discoveries toward preclinical development and, ultimately, clinical translation. To learn more about Longevica's pipeline, research publications, or strategic partnership opportunities, visit https://longevica.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260929979908/en/ |
